Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus PREDNISOLONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus PREDNISOLONE SODIUM PHOSPHATE.
CORTIFOAM vs PREDNISOLONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Agonist of glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of pro-inflammatory cytokines, and suppression of immune cell activity.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Initial dose: 5-60 mg orally or intravenously once daily or divided every 12-24 hours; range 5-60 mg/day. For acute conditions, 40-60 mg once daily.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is 2.1–3.5 hours in adults (mean 2.6 h). Clinical context: Short half-life supports twice-daily dosing for most conditions; prolonged in hepatic impairment (up to 8 h).
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal excretion of inactive metabolites (primarily prednisolone) accounts for >80% of elimination; less than 10% excreted unchanged. Biliary/fecal excretion is negligible (<5%).
Category C
Category D/X
Corticosteroid
Corticosteroid